Berthier et al..png

Speech and language outcome measures in clinical trials of Alzheimer’s and Parkinson’s diseases

Speech and language outcome measures in clinical trials of Alzheimer’s and Parkinson’s diseases - https://www.tandfonline.com/doi/full/10.1080/14737175.2025.2600616

Alongside core diagnostic symptoms, Alzheimer’s disease (AD) and Parkinson’s disease (PD) involve early and pervasive speech-language impairments (SLI), often appearing in preclinical stages and capturing disease severity. However, speech language outcome measures are under-represented in clinical trials, missing out on critical clinical outcome assessments (COAs).

Buscador UdeSA